000			03302nam a22003857a 4500
008			190521s20192019 xxu||||| |||| 00| 0 eng d
022			_a1753-4658
024			_a10.1177/1753466619841234 [doi]
024			_aPMC6454637 [pmc]
040			_aOvid MEDLINE(R)
099			_a30958102
245			_aFiducial marker placement with electromagnetic navigation bronchoscopy: a subgroup analysis of the prospective, multicenter NAVIGATE study.
251			_aTherapeutic Advances in Respiratory Disease. 13:1753466619841234, 2019 Jan-Dec.
252			_aTherap. adv. respir. dis.. 13:1753466619841234, 2019 Jan-Dec.
253			_aTherapeutic advances in respiratory disease
260			_c2019
260			_fFY2019
265			_sppublish
266			_d2019-05-21
520			_aBACKGROUND: Fiducial markers (FMs) help direct stereotactic body radiation therapy (SBRT) and localization for surgical resection in lung cancer management. We report the safety, accuracy, and practice patterns of FM placement utilizing electromagnetic navigation bronchoscopy (ENB).
520			_aCONCLUSION: ENB is an accurate and versatile tool to place FMs for SBRT and localization for surgical resection with low complication rates. The ability to perform a biopsy safely in the same procedure can also increase efficiency. The impact of practice pattern variations on therapeutic effectiveness requires further study.
520			_aMETHODS: NAVIGATE is a global, prospective, multicenter, observational cohort study of ENB using the superDimensionTM navigation system. This prospectively collected subgroup analysis presents the patient demographics, procedural characteristics, and 1-month outcomes in patients undergoing ENB-guided FM placement. Follow up through 24 months is ongoing.
520			_aRESULTS: Two-hundred fifty-eight patients from 21 centers in the United States were included. General anesthesia was used in 68.2%. Lesion location was confirmed by radial endobronchial ultrasound in 34.5% of procedures. The median ENB procedure time was 31.0 min. Concurrent lung lesion biopsy was conducted in 82.6% (213/258) of patients. A mean of 2.2 +/- 1.7 FMs (median 1.0 FMs) were placed per patient and 99.2% were accurately positioned based on subjective operator assessment. Follow-up imaging showed that 94.1% (239/254) of markers remained in place. The procedure-related pneumothorax rate was 5.4% (14/258) overall and 3.1% (8/258) grade 2 based on the Common Terminology Criteria for Adverse Events scale. The procedure-related grade 4 respiratory failure rate was 1.6% (4/258). There were no bronchopulmonary hemorrhages.
520			_aTRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02410837.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Franklin Square Medical Center
656			_aAngelos Center for Lung Disease
657			_aJournal Article
657			_aResearch Support, Non-U.S. Gov't
700			_aKrimsky, William S
790			_aAnciano CJ, Bowling MR, Folch EE, Kazakov J, Khandhar SJ, Krimsky WS, LeMense GP, Linden PA, Murillo BA, Nead MA, Pritchett MA, Teba CV, Towe CW, Williams T
856			_uhttps://dx.doi.org/10.1177/1753466619841234 _zhttps://dx.doi.org/10.1177/1753466619841234
942			_cART _dArticle
999			_c4281 _d4281